The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...
it would seem that GLP-1 use for weight loss would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this. The pharmacy benefit manager Prime ...
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...
Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took researchers by surprise.
Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
The latter has made little difference: the popularity of Ozempic and other GLP-1 ... weight loss with regular use. “A couple of years ago there was an article published in Nature about an ...
Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.